PDCD1 and lung carcinoma: Still, the use of mTOR inhibitor in combination with the PD-1 antibody in the mouse lung cancer model resulted in a significant inhibition of tumor growth, an increase in tumor-infiltrating lymphocytes (TILs) number, and a significant reduction in Tregs number [51].